Patients ask me about supplements every week. They bring bottles from Amazon, health food stores, podcasts, and social media. They want something natural. They want something gentler. They want something they can buy without asking permission. I understand the instinct. Psychiatric medications have side effects, cost, stigma, and disappointment. But the supplement aisle is not a sanctuary. It is a marketplace that could turn dangerous.
That matters because supplements in the United States are not regulated like prescription drugs. The Food and Drug Administration (FDA) does not approve most dietary supplements for safety or effectiveness before they reach the shelf. A company can sell a product long before science catches up. Labels sound medical and marketing sound like clean evidence that often does not exist. Still, I do not dismiss all supplements. Some have real randomized controlled trial evidence. Some deserve a place in psychiatric care. But only as adjuncts. Not as replacements for a real diagnosis, good psychotherapy, prescription treatment when indicated, or follow-up with a clinician who knows the difference between symptom relief and wishful thinking. That is the line I care about. Not hype. Not ideology. Evidence.
Depression is where the strongest evidence lives.
If you want the short answer, depression is the psychiatric condition where the supplement data are most developed. Omega-3 fatty acids, especially eicosapentaenoic acid (EPA) dominant formulations, have some of the best adjunctive evidence in major depressive disorder. The signal is not dramatic and it is not a miracle. But across randomized trials and meta-analyses, EPA-rich fish oil has shown modest benefit, especially when added to antidepressants rather than used alone. This is one of the few over-the-counter options that a serious psychiatrist can discuss without rolling their eyes.
L-methylfolate also deserves a place in this conversation. In patients with treatment-resistant depression, adjunctive 15 mg daily has shown benefit in randomized trials. This makes biologic sense. Folate metabolism matters for monoamine synthesis, and some patients carry folate pathway problems or have nutritional and inflammatory burdens that make this pathway more relevant. I do not see L-methylfolate as a wellness product. I see it as a targeted augmentation strategy. S-adenosylmethionine (SAM-e) has also shown adjunctive antidepressant signal. The evidence is not as clean or as durable as many marketing claims suggest, but there is enough randomized evidence to take it seriously. The problem is that many patients hear “natural antidepressant” and assume harmless. That is sloppy thinking. SAM-e can activate people, can complicate bipolar illness, and deserves the same caution we would use with any agent that shifts mood.
Probiotics are another area with real momentum. The gut-brain axis is no longer fringe talk. Some randomized trials and meta-analyses suggest that certain probiotic strains can reduce depressive symptoms, and sometimes anxiety symptoms, when used as adjuncts. But this field has a serious standardization problem. Probiotics are not one thing, strains matter and dose matters. Product integrity matters. A good trial on one blend does not validate every bottle on the shelf. There is also meaningful evidence for a few plant-based agents used in depression, especially saffron and, in selected cases, curcumin and St. John’s wort. Saffron has produced encouraging randomized trial results in mild to moderate depression. Curcumin has an emerging adjunctive signal. St. John’s wort has evidence too, but I approach it with caution because the drug interaction burden is real and sometimes dangerous. Patients hear “herbal” and think safe. Cytochrome P450 enzymes do not care about branding. Finally, vitamin D and zinc also enter this conversation, especially when deficiency is present, but I would not oversell them as universal antidepressants. Deficiency correction is good medicine. Magical thinking is not.
Anxiety has fewer winners than the internet claims.
The supplement industry loves anxiety because anxiety is common, subjective, and easy to market to. The evidence is much narrower than the marketing. Lavender oil, particularly standardized oral preparations, has some of the better randomized data for generalized anxiety and mixed anxiety states. It is one of the few over-the-counter options with reasonable evidence base and a tolerable side effect profile. It is approved in many European countries for the treatment of anxiety.
Ashwagandha has a growing evidence signal for stress and anxiety reduction, but the data remain less mature than the internet suggests. Small studies, mixed methods, and variable products limit confidence. I would call it promising, not proven. Kava is the classic example of why efficacy is not enough. It may reduce anxiety in some studies, but concerns about hepatotoxicity and product variability have kept it from being a casual recommendation. A supplement does not become a smart choice just because it worked in a small trial.
Sleep is where people overspend and underthink.
Most people who want a supplement for sleep are not asking for a nuanced conversation. They want to be knocked out. That mindset creates bad decisions. Melatonin has real evidence, but the strongest evidence is for circadian rhythm problems such as jet lag, shift work disruption, and delayed sleep phase. That is different from saying melatonin fixes every form of insomnia. It does not. Timing matters. Dose matters. The problem matters.
Magnesium (glycinate specifically) has become a social media celebrity. The truth is more modest. Sleep data are mixed overall, but recent randomized evidence with magnesium L-threonate (Magtein) suggests improvement in sleep quality and daytime functioning in adults with sleep complaints. That is encouraging. It is not enough to justify sweeping claims about every magnesium product for every tired person. When a field has one promising trial and a thousand influencers, science is not the loudest voice in the room.
Schizophrenia is where false hope does real damage.
This is where I get blunt. No supplement replaces antipsychotic treatment in schizophrenia. None. Anyone telling patients with psychosis to swap evidence-based treatment for a supplement stack is playing with fire. That said, some adjunctive strategies deserve attention. N-acetylcysteine (NAC) has the strongest serious signal here. Meta-analyses of randomized trials suggest benefit for negative symptoms and some cognitive domains, particularly over longer treatment periods. That matters because negative symptoms are disabling, persistent, and often poorly addressed. L-methylfolate and folate-based strategies have also shown signal for negative symptoms in schizophrenia, especially in patients whose biology makes folate metabolism relevant. This is not a cure. It is a possible biologically informed adjunct.
What should patients and clinicians do now
We need a more honest middle ground. Supplements are not all garbage. They are not all medicine either. Some belong in the treatment plan. Many do not. The job is not to worship them or mock them. The job is to separate signal from noise. When I consider a supplement in psychiatric care, I ask five simple questions:
- Was it tested in randomized controlled trials?
- Was it used as an adjunct or as monotherapy?
- What dose and formulation were studied?
- What interactions matter?
- What exact symptoms were improved?
That last question is where most supplement marketing falls apart. “Mood support” is not a diagnosis. “Brain health” is not an outcome. If a supplement helped negative symptoms in schizophrenia, say that. If it helped treatment-resistant depression, say that. If it helped delayed sleep phase, say that. Precision protects patients. Patients also deserve product quality. Third-party testing matters. Standardized formulations matter. A cheap bottle with a confident label is not evidence. It is packaging. Psychiatry does not need more hype. It needs cleaner evidence, better regulation, and more courage from clinicians to say two things at once. Yes, some supplements help. No, hope is not the same thing as proof. That is the future patients deserve.
Muhamad Aly Rifai is a nationally recognized psychiatrist, internist, and addiction medicine specialist based in the Greater Lehigh Valley, Pennsylvania. He is the founder, CEO, and chief medical officer of Blue Mountain Psychiatry, a leading multidisciplinary practice known for innovative approaches to mental health, addiction treatment, and integrated care. Dr. Rifai currently holds the prestigious Lehigh Valley Endowed Chair of Addiction Medicine, reflecting his leadership in advancing evidence-based treatments for substance use disorders.
Board-certified in psychiatry, internal medicine, addiction medicine, and consultation-liaison (psychosomatic) psychiatry, Dr. Rifai is a fellow of the American College of Physicians (FACP), the American Psychiatric Association (FAPA), and the Academy of Consultation-Liaison Psychiatry (FACLP). He is also a former president of the Lehigh Valley Psychiatric Society, where he championed access to community-based psychiatric care and physician advocacy.
A thought leader in telepsychiatry, ketamine treatment, and the intersection of medicine and mental health, Dr. Rifai frequently writes and speaks on physician justice, federal health care policy, and the ethical use of digital psychiatry.
You can learn more about Dr. Rifai through his Wikipedia page, connect with him on LinkedIn, X (formerly Twitter), Facebook, or subscribe to his YouTube channel. His podcast, The Virtual Psychiatrist, offers deeper insights into topics at the intersection of mental health and medicine. Explore all of Dr. Rifai’s platforms and resources via his Linktree.
